Clinical Trials

Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), and TAGRISSO (osimertinib), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC).

LORBRENA significantly improves progression-free survival in first-line ALK-positive lung cancer

Pfizer announced that the Phase 3 CROWN study of LORBRENA (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) met its primary endpoint by demonstrating significantly improved progression-free survival (PFS), as compared to XALKORI (crizotinib).

RLF-100 shown to deliver rapid recovery from respiratory failure in Covid-19 patients

NeuroRx and Relief Therapeutics said that RLF-100 (aviptadil) delivered quick recovery from respiratory failure in the most critically ill patients suffering from Covid-19 in a phase 2/3 clinical trial.

AbCellera provides Covid-19 programme update with start of phase 3 clinical trials

AbCellera announced that LY-CoV555, a human antibody discovered by AbCellera in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and co-developed with Eli Lilly and Company (Lilly) as a potential treatment and prophylaxis for Covi-19, has progressed to Phase 3 clinical trials. A first-of-its-kind, the Lilly-sponsored trial will use customized mobile research units to conduct the study at long-term care facilities across the United States.

SAB Biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce fully human polyclonal antibodies without the need for human donors, announced that the first participant has been dosed in its Phase 1 clinical trial evaluating SAB-176 for the treatment of seasonal influenza.

Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia

Roche’s Actemra/RoActemra (tocilizumab) has failed to achieve the primary endpoint in the phase III trial, which included hospitalised patients with severe Covid-19 associated pneumonia.

AstraZeneca’s Farxiga succeeds in phase 3 trial in chronic kidney disease

AstraZeneca said that Farxiga (dapagliflozin) has succeeded in a phase 3 trial in chronic kidney disease (CKD) by meeting all its primary and secondary endpoints.

AI Therapeutics announces start of phase II trial of LAM-002A to treat Covid-19 patients

AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed Covid-19 patients in collaboration with Yale University.

NeoImmuneTech gets IND clearance for NT-I7 trial in locally recurrent SCCHN

NeoImmuneTech announced receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, in a Window-of-Opportunity trial for patients with locally recurrent squamous cell carcinoma of head and neck (SCCHN) undergoing salvage surgery.